Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A9BI
|
|||
| Former ID |
DIB003184
|
|||
| Drug Name |
Hi-8 PrimeBoost therapeutic melanoma vaccine
|
|||
| Synonyms |
Hi-8 MEL; Melanoma therapeutic vaccine, Oxxon; PSG2.Mel3; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxford BioMedica; Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Lead Hi-8 PrimeBoost therapeutic melanoma vaccine, Oxxon; Pharmaccine therapy (melanoma), Oxxon; DNA/MVA immunotherapy (melanoma), Oxxon; MEL-1 immunotherapy (melanoma), Oxxon; Melanoma immunotherapy (Prime-Boost), Oxxon
Click to Show/Hide
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Company |
Oxxon Therapeutics Ltd
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013884) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.